Drug Profile

Bezisterim - BioVie

Alternative Names: 17α-ethynyl-5-androstene-3β,7β,17β-triol; 3α-ethynyl-androst-5-ene-3β,7β,17β-triol; HE 3286; NE-3107; Triolex^®

Latest Information Update: 13 Aug 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Hollis-Eden Pharmaceuticals
Developer BioVie; Harbor Therapeutics; National Institutes of Health (USA); NeurMedix
Class Anti-inflammatories; Antidementias; Antiepileptic drugs; Antifibrotics; Antiglaucomas; Antihyperglycaemics; Antimigraines; Antineoplastics; Antiparkinsonians; Antirheumatics; Antivirals; Hormones; Insulin sensitisers; Nootropics; Obesity therapies; Small molecules
Mechanism of Action Adiponectin stimulants; Interleukin 23 inhibitors; Interleukin 6 inhibitors; Mitogen-activated protein kinase 1 inhibitors; Mitogen-activated protein kinase 3 inhibitors; NF-kappa B inhibitors; Tumour necrosis factor alpha inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes - Cystic fibrosis

Phase III Alzheimer's disease
Phase II Parkinson's disease; Post acute COVID 19 syndrome; Traumatic brain injuries
No development reported Drug-induced dyskinesia; Multiple myeloma; Prostate cancer
Discontinued Amyotrophic lateral sclerosis; Cognition disorders; Cystic fibrosis; Epilepsy; Glaucoma; Huntington's disease; Migraine; Myositis; Optic neuritis; Rheumatoid arthritis; Type 1 diabetes mellitus; Type 2 diabetes mellitus; Ulcerative colitis; Uveitis

06 Aug 2026 Efficacy, pharmacodynamic and adverse events data from phase IIb SUNRISE-PD trial in Parkinsons Disease released by BioVie
31 May 2026 BioVie completes a phase II SUNRISE-PD trial in Parkinsons disease (Early stage disease) in USA (PO) (NCT06757010)
26 May 2026 BioVie completes enrolment in the phase II ADdRESs-LC trial for Post-acute COVID-19 syndrome in USA (PO, Capsule)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com